It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Anti-malaria API facility will be operational in 15-18 months
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company is eligible for 12 months exclusivity from launch
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The aim is to create new genomics solutions that could combat cancer and advance market access
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
If approved it will bring a second source of MMR vaccine to the US market
Subscribe To Our Newsletter & Stay Updated
